HU204511B - Process for producing quinolone derivatives - Google Patents
Process for producing quinolone derivatives Download PDFInfo
- Publication number
- HU204511B HU204511B HU886294A HU629488A HU204511B HU 204511 B HU204511 B HU 204511B HU 886294 A HU886294 A HU 886294A HU 629488 A HU629488 A HU 629488A HU 204511 B HU204511 B HU 204511B
- Authority
- HU
- Hungary
- Prior art keywords
- formula
- fluoro
- mixture
- compound
- methyl
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 40
- 150000007660 quinolones Chemical class 0.000 title abstract description 8
- 150000001875 compounds Chemical class 0.000 claims abstract description 83
- 238000002360 preparation method Methods 0.000 claims abstract description 9
- 150000004703 alkoxides Chemical class 0.000 claims abstract description 3
- 150000001412 amines Chemical class 0.000 claims abstract description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims abstract description 3
- 150000007529 inorganic bases Chemical class 0.000 claims abstract description 3
- 150000007530 organic bases Chemical class 0.000 claims abstract description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 42
- -1 thiolate ion Chemical class 0.000 claims description 24
- 238000007363 ring formation reaction Methods 0.000 claims description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 10
- 229910052736 halogen Inorganic materials 0.000 claims description 9
- 150000002367 halogens Chemical class 0.000 claims description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 239000011593 sulfur Substances 0.000 claims description 4
- 230000000269 nucleophilic effect Effects 0.000 claims description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 3
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 3
- 230000026030 halogenation Effects 0.000 claims description 2
- 238000005658 halogenation reaction Methods 0.000 claims description 2
- 239000007858 starting material Substances 0.000 claims 1
- 238000006798 ring closing metathesis reaction Methods 0.000 abstract description 4
- 238000006177 thiolation reaction Methods 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 108
- 239000000203 mixture Substances 0.000 description 83
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 56
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 38
- 239000000243 solution Substances 0.000 description 31
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 27
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 24
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 21
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
- 239000000047 product Substances 0.000 description 19
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 16
- 239000007787 solid Substances 0.000 description 16
- 239000010410 layer Substances 0.000 description 15
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 14
- ZUMVHPMHCIKNFT-UHFFFAOYSA-N 7-fluoro-1-methyl-3-methylsulfonylquinolin-4-one Chemical compound C1=C(F)C=C2N(C)C=C(S(C)(=O)=O)C(=O)C2=C1 ZUMVHPMHCIKNFT-UHFFFAOYSA-N 0.000 description 13
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 12
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 12
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 12
- 229910052757 nitrogen Inorganic materials 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 11
- 239000003921 oil Substances 0.000 description 11
- 238000010992 reflux Methods 0.000 description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 9
- 239000012267 brine Substances 0.000 description 9
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 9
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 7
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 235000019253 formic acid Nutrition 0.000 description 7
- 229910052801 chlorine Inorganic materials 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 238000000227 grinding Methods 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 description 6
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 6
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 239000000460 chlorine Substances 0.000 description 5
- 239000012043 crude product Substances 0.000 description 5
- UYGONJYYUKVHDD-UHFFFAOYSA-N flosequinan Chemical compound C1=C(F)C=C2N(C)C=C(S(C)=O)C(=O)C2=C1 UYGONJYYUKVHDD-UHFFFAOYSA-N 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 239000003208 petroleum Substances 0.000 description 5
- RMBAVIFYHOYIFM-UHFFFAOYSA-M sodium methanethiolate Chemical compound [Na+].[S-]C RMBAVIFYHOYIFM-UHFFFAOYSA-M 0.000 description 5
- 239000012265 solid product Substances 0.000 description 5
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 4
- CQBGMEVMWSNQLD-UHFFFAOYSA-N 1-[4-fluoro-2-(methylamino)phenyl]-2-methylsulfinylethanone Chemical compound CNC1=CC(F)=CC=C1C(=O)CS(C)=O CQBGMEVMWSNQLD-UHFFFAOYSA-N 0.000 description 4
- LKFQKWKCBWMOIN-UHFFFAOYSA-N 1-[4-fluoro-2-(methylamino)phenyl]-2-methylsulfonylethanone Chemical compound CNC1=CC(F)=CC=C1C(=O)CS(C)(=O)=O LKFQKWKCBWMOIN-UHFFFAOYSA-N 0.000 description 4
- KMQUWNASNVJFPB-UHFFFAOYSA-N 1-[4-fluoro-2-(methylamino)phenyl]ethanone Chemical compound CNC1=CC(F)=CC=C1C(C)=O KMQUWNASNVJFPB-UHFFFAOYSA-N 0.000 description 4
- VOKLUGVCKPXDJE-UHFFFAOYSA-N 2-oxo-n-phenylpropanamide Chemical compound CC(=O)C(=O)NC1=CC=CC=C1 VOKLUGVCKPXDJE-UHFFFAOYSA-N 0.000 description 4
- PDOYKCJODSQLCN-UHFFFAOYSA-N 7-fluoro-1-methyl-3-methylsulfanylquinolin-4-one Chemical compound FC1=CC=C2C(=O)C(SC)=CN(C)C2=C1 PDOYKCJODSQLCN-UHFFFAOYSA-N 0.000 description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 235000019341 magnesium sulphate Nutrition 0.000 description 4
- 239000012299 nitrogen atmosphere Substances 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 238000004821 distillation Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 150000002431 hydrogen Chemical class 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- BTUDHIIWDNHHLA-UHFFFAOYSA-N n-[5-fluoro-2-(2-methylsulfanylacetyl)phenyl]-n-methylformamide Chemical compound CSCC(=O)C1=CC=C(F)C=C1N(C)C=O BTUDHIIWDNHHLA-UHFFFAOYSA-N 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- CSEMGLVHVZRXQF-UHFFFAOYSA-N 1-(2-chloro-4-fluorophenyl)ethanone Chemical compound CC(=O)C1=CC=C(F)C=C1Cl CSEMGLVHVZRXQF-UHFFFAOYSA-N 0.000 description 2
- RLOFMBAAEKGVPT-UHFFFAOYSA-N 1-[4-fluoro-2-(methylamino)phenyl]-2-methylsulfanylethanone Chemical compound CNC1=CC(F)=CC=C1C(=O)CSC RLOFMBAAEKGVPT-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- ORWKVZNEPHTCQE-UHFFFAOYSA-N acetic formic anhydride Chemical compound CC(=O)OC=O ORWKVZNEPHTCQE-UHFFFAOYSA-N 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- BJDCWCLMFKKGEE-CMDXXVQNSA-N chembl252518 Chemical compound C([C@@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@H](O)[C@@H]4C BJDCWCLMFKKGEE-CMDXXVQNSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229960001701 chloroform Drugs 0.000 description 2
- 230000006198 deformylation Effects 0.000 description 2
- 238000006344 deformylation reaction Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 230000002140 halogenating effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 2
- 125000006216 methylsulfinyl group Chemical group [H]C([H])([H])S(*)=O 0.000 description 2
- GMPRLVJZTKKNIB-UHFFFAOYSA-N n-(5-fluoro-2-methylsulfinylphenyl)-n-methyl-2-oxopropanamide Chemical compound CC(=O)C(=O)N(C)C1=CC(F)=CC=C1S(C)=O GMPRLVJZTKKNIB-UHFFFAOYSA-N 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- ZDPAWHACYDRYIW-UHFFFAOYSA-N 1-(4-fluorophenyl)ethanone Chemical compound CC(=O)C1=CC=C(F)C=C1 ZDPAWHACYDRYIW-UHFFFAOYSA-N 0.000 description 1
- XEMZUYMKEAZKLE-UHFFFAOYSA-N 2-oxo-N-phenyl-3-sulfonylpropanamide Chemical compound S(=O)(=O)=CC(=O)C(=O)NC1=CC=CC=C1 XEMZUYMKEAZKLE-UHFFFAOYSA-N 0.000 description 1
- NKTZRZBSADJAJL-UHFFFAOYSA-N 4-fluoro-2-(methylamino)benzoic acid Chemical compound CNC1=CC(F)=CC=C1C(O)=O NKTZRZBSADJAJL-UHFFFAOYSA-N 0.000 description 1
- KVGQFTUVCDHXBT-UHFFFAOYSA-N 7-fluoro-1,3-dimethylquinoline-4-thione Chemical compound FC1=CC=C2C(=S)C(C)=CN(C)C2=C1 KVGQFTUVCDHXBT-UHFFFAOYSA-N 0.000 description 1
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 239000003377 acid catalyst Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000002027 dichloromethane extract Substances 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001153 fluoro group Chemical class F* 0.000 description 1
- VGGRCVDNFAQIKO-UHFFFAOYSA-N formic anhydride Chemical compound O=COC=O VGGRCVDNFAQIKO-UHFFFAOYSA-N 0.000 description 1
- 230000022244 formylation Effects 0.000 description 1
- 238000006170 formylation reaction Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-M methanethiolate Chemical compound [S-]C LSDPWZHWYPCBBB-UHFFFAOYSA-M 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- VNRLQGFUUANBJH-UHFFFAOYSA-N n-[2-(2-chloroacetyl)-5-fluorophenyl]-n-methylformamide Chemical compound O=CN(C)C1=CC(F)=CC=C1C(=O)CCl VNRLQGFUUANBJH-UHFFFAOYSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- ZGHLCBJZQLNUAZ-UHFFFAOYSA-N sodium sulfide nonahydrate Chemical compound O.O.O.O.O.O.O.O.O.[Na+].[Na+].[S-2] ZGHLCBJZQLNUAZ-UHFFFAOYSA-N 0.000 description 1
- 229940048181 sodium sulfide nonahydrate Drugs 0.000 description 1
- WMDLZMCDBSJMTM-UHFFFAOYSA-M sodium;sulfanide;nonahydrate Chemical compound O.O.O.O.O.O.O.O.O.[Na+].[SH-] WMDLZMCDBSJMTM-UHFFFAOYSA-M 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Physical Or Chemical Processes And Apparatus (AREA)
- Quinoline Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB878726950A GB8726950D0 (en) | 1987-11-18 | 1987-11-18 | Chemical process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUT53085A HUT53085A (en) | 1990-09-28 |
| HU204511B true HU204511B (en) | 1992-01-28 |
Family
ID=10627131
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU886294A HU204511B (en) | 1987-11-18 | 1988-11-07 | Process for producing quinolone derivatives |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US5011931A (enExample) |
| EP (2) | EP0317149B1 (enExample) |
| JP (1) | JPH02502013A (enExample) |
| KR (1) | KR890701563A (enExample) |
| AT (1) | ATE69221T1 (enExample) |
| AU (1) | AU628305B2 (enExample) |
| BG (1) | BG50157A3 (enExample) |
| CS (1) | CS274487B2 (enExample) |
| DD (1) | DD290188A5 (enExample) |
| DE (1) | DE3866086D1 (enExample) |
| ES (1) | ES2038310T3 (enExample) |
| FI (1) | FI91063C (enExample) |
| GB (1) | GB8726950D0 (enExample) |
| GR (1) | GR3003378T3 (enExample) |
| HU (1) | HU204511B (enExample) |
| IE (1) | IE883366L (enExample) |
| IL (1) | IL88358A (enExample) |
| MX (1) | MX168918B (enExample) |
| NZ (1) | NZ227008A (enExample) |
| PH (1) | PH27439A (enExample) |
| PL (1) | PL157191B1 (enExample) |
| PT (1) | PT89024B (enExample) |
| RO (1) | RO104615B1 (enExample) |
| SU (1) | SU1766255A3 (enExample) |
| TW (1) | TW204344B (enExample) |
| WO (1) | WO1989004827A1 (enExample) |
| YU (1) | YU46989B (enExample) |
| ZA (1) | ZA888241B (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8726950D0 (en) * | 1987-11-18 | 1987-12-23 | Boots Co Plc | Chemical process |
| GB8804016D0 (en) * | 1988-02-22 | 1988-03-23 | Boots Co Plc | Therapeutic agents |
| US6110489A (en) * | 1998-05-01 | 2000-08-29 | Cutler; Neal R. | Use of quinolines and quinolones to treat male erectile dysfunction |
| US6194433B1 (en) | 1998-10-05 | 2001-02-27 | Neal R. Cutler | Sexual dysfunction in females |
| US6132753A (en) * | 1998-05-01 | 2000-10-17 | Neal R. Cutler | Treatment of sexual dysfunction in certain patient groups |
| US6426084B1 (en) * | 2000-06-19 | 2002-07-30 | Neal R. Cutler | Treatment of sexual dysfunction in certain patient groups |
| US6132757A (en) * | 1998-05-01 | 2000-10-17 | Neal R. Cutler | Treatment of sexual dysfunction in certain patient groups |
| US6303135B1 (en) | 1999-07-08 | 2001-10-16 | Neal R. Cutler | Use of quinolines and quinolones to treat male erectile dysfunction |
| US6307050B1 (en) * | 2000-08-29 | 2001-10-23 | R. T. Alamo Venture I Llc | Method of synthesizing flosequinan from 4-fluoroanthranilic acid |
| US6451813B1 (en) | 2001-01-26 | 2002-09-17 | R. T. Alamo Ventures I, Llc | Treatment of gastroparesis in certain patient groups |
| US6458804B1 (en) * | 2001-01-26 | 2002-10-01 | R.T. Alamo Venturesi, Llc | Methods for the treatment of central nervous system disorders in certain patient groups |
| US6562838B2 (en) | 2001-01-26 | 2003-05-13 | R. T. Alamo Ventures I, L.L.C. | Treatment of cardiovascular disease with quinolinone enantiomers |
| US6531603B1 (en) | 2001-06-29 | 2003-03-11 | Grayson Walker Stowell | Polymorphic forms of 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone |
| US6573382B2 (en) | 2001-06-29 | 2003-06-03 | Grayson Walker Stowell | Polymorphic forms of 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone |
| US6657061B2 (en) | 2001-06-29 | 2003-12-02 | Grayson Walker Stowell | Polymorphic forms of 6-[4-1(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone |
| US6388080B1 (en) | 2001-06-29 | 2002-05-14 | Grayson Walker Stowell | Polymorphic forms of 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone |
| US6596871B2 (en) | 2001-06-29 | 2003-07-22 | Grayson Walker Stowell | Polymorphic forms of 6-[4-(1-cyclohexyl-1h-tetraol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone |
| US6660864B2 (en) | 2001-06-29 | 2003-12-09 | Grayson Walker Stowell | Polymorphic forms of 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone |
| JP4202250B2 (ja) | 2001-07-25 | 2008-12-24 | バイオマリン ファーマシューティカル インコーポレイテッド | 血液脳関門輸送を調節するための組成物および方法 |
| US6649764B2 (en) * | 2001-10-25 | 2003-11-18 | R. T. Alamo Ventures I, Llc | Stereospecific enrichment of heterocyclic enantiomers |
| US7041677B2 (en) * | 2002-03-01 | 2006-05-09 | R.T. Alamo Ventures I, Llc | Use of monochloroflosequinan in the treatment of sexual dysfunction |
| US6730790B2 (en) * | 2002-03-01 | 2004-05-04 | R.T. Alamo Ventures I. Llc | Chlorinated heterocyclic compounds and methods of synthesis |
| EP3827747A1 (en) | 2005-04-28 | 2021-06-02 | Otsuka Pharmaceutical Co., Ltd. | Pharma-informatics system |
| CN101594878A (zh) | 2006-09-18 | 2009-12-02 | 雷普特药品公司 | 通过给予受体相关蛋白（rap）-缀合物对肝病症的治疗 |
| DK3395372T3 (da) | 2009-02-20 | 2022-04-19 | Enhanx Biopharm Inc | System til afgivelse af glutathion-baseret medikament |
| CN110075069A (zh) | 2009-05-06 | 2019-08-02 | 实验室护肤股份有限公司 | 包含活性剂-磷酸钙颗粒复合物的皮肤递送组合物及其应用 |
| US20120077778A1 (en) | 2010-09-29 | 2012-03-29 | Andrea Bourdelais | Ladder-Frame Polyether Conjugates |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3920699A (en) * | 1974-04-26 | 1975-11-18 | Warner Lambert Co | Process for the cyclization of aryl(methylsulfinyl)-methyl ketones and compounds produced thereby |
| US4192873A (en) * | 1976-11-25 | 1980-03-11 | Ciba-Geigy Corporation | Anti-inflammatory 2-sulphonyl- (or -sulphinyl)-2'-aminoacetophenones |
| NZ193167A (en) * | 1979-03-27 | 1984-08-24 | Boots Co Plc | Quinoline derivatives and pharmaceutical compositions |
| IE51542B1 (en) * | 1980-09-26 | 1987-01-07 | Boots Co Ltd | Therapeutic agents |
| FR2532939A1 (fr) * | 1982-09-13 | 1984-03-16 | Roussel Uclaf | Nouveaux derives de l'acide 4-hydroxy 3-quinoleine carboxylique substitues en 2, leur preparation, leur application comme medicament, les compositions les renfermant et les nouveaux intermediaires obtenus |
| US4552884A (en) * | 1984-01-13 | 1985-11-12 | The Boots Company Plc | Method of treating heart disease |
| FR2566405B1 (fr) * | 1984-06-25 | 1986-09-26 | Roussel Uclaf | Nouveaux derives de l'acide 4-hydroxy 3-quinoleine carboxylique substitues en 2 par une fonction aminee, leur preparation, leur application comme medicaments, les compositions les renfermant et les intermediaires nouveaux obtenus |
| GB8515209D0 (en) * | 1985-06-15 | 1985-07-17 | Boots Co Plc | Therapeutic agents |
| GB8627698D0 (en) * | 1986-11-20 | 1986-12-17 | Boots Co Plc | Therapeutic agents |
| GB8726950D0 (en) * | 1987-11-18 | 1987-12-23 | Boots Co Plc | Chemical process |
-
1987
- 1987-11-18 GB GB878726950A patent/GB8726950D0/en active Pending
-
1988
- 1988-11-03 ZA ZA888241A patent/ZA888241B/xx unknown
- 1988-11-07 HU HU886294A patent/HU204511B/hu not_active IP Right Cessation
- 1988-11-07 DE DE8888310463T patent/DE3866086D1/de not_active Expired - Fee Related
- 1988-11-07 AT AT88310463T patent/ATE69221T1/de not_active IP Right Cessation
- 1988-11-07 KR KR1019890701326A patent/KR890701563A/ko not_active Ceased
- 1988-11-07 ES ES198888310463T patent/ES2038310T3/es not_active Expired - Lifetime
- 1988-11-07 EP EP88310463A patent/EP0317149B1/en not_active Expired - Lifetime
- 1988-11-07 JP JP63508842A patent/JPH02502013A/ja active Pending
- 1988-11-07 RO RO140740A patent/RO104615B1/ro unknown
- 1988-11-07 US US07/378,216 patent/US5011931A/en not_active Expired - Fee Related
- 1988-11-07 AU AU26163/88A patent/AU628305B2/en not_active Ceased
- 1988-11-07 WO PCT/GB1988/000952 patent/WO1989004827A1/en not_active Ceased
- 1988-11-07 EP EP88909581A patent/EP0343206A1/en active Pending
- 1988-11-09 IE IE883366A patent/IE883366L/xx unknown
- 1988-11-09 PH PH37784A patent/PH27439A/en unknown
- 1988-11-10 IL IL88358A patent/IL88358A/xx unknown
- 1988-11-10 MX MX013748A patent/MX168918B/es unknown
- 1988-11-11 TW TW077107879A patent/TW204344B/zh active
- 1988-11-11 YU YU209788A patent/YU46989B/sh unknown
- 1988-11-15 CS CS748988A patent/CS274487B2/cs unknown
- 1988-11-16 DD DD88321853A patent/DD290188A5/de not_active IP Right Cessation
- 1988-11-17 PT PT89024A patent/PT89024B/pt not_active IP Right Cessation
- 1988-11-18 NZ NZ227008A patent/NZ227008A/en unknown
- 1988-11-18 PL PL1988275880A patent/PL157191B1/pl unknown
-
1989
- 1989-05-17 SU SU894614311A patent/SU1766255A3/ru active
- 1989-07-13 FI FI893405A patent/FI91063C/fi not_active IP Right Cessation
- 1989-07-17 BG BG089219A patent/BG50157A3/xx unknown
-
1991
- 1991-03-01 US US07/663,085 patent/US5079264A/en not_active Expired - Fee Related
- 1991-12-18 GR GR91402063T patent/GR3003378T3/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HU204511B (en) | Process for producing quinolone derivatives | |
| LU88049A1 (fr) | Bis(acyloxy-o)borate de l'(acide-o3,o4-6,7-substitue-8-alcoxy-l-cyclopropyl-1,4-dihydro-4-oxo-3-quinoleinecarboxylique et le sel de ce dernier,ainsi que leur procede de preparation | |
| JP2000501413A (ja) | ２―クロロチアゾール化合物の製法 | |
| SE8700597D0 (sv) | Mellanprodukter for framstellning av eburnamoninderivat och forfarande for framstellning av dessa mellanprodukter | |
| NO158673B (no) | Analogifremgangsm te ved fremstilling av terapeutisk aktive azurenderivater. | |
| JPH04210957A (ja) | シクロペンテン化合物の製法 | |
| JP3338854B2 (ja) | 新しいアレノ〔ｅ〕インドールの製造方法 | |
| Takeshima et al. | Formation of 3-substituted 2-iminocyclopentanedithiocarboxylic acids and N-[amino (dimercapto) methyl]-2-methylcyclopentanimine from 2-substituted cyclopentanones. Some reactions of the imino-dithiocarb-oxylic acids | |
| FI81782C (fi) | Foerfarande foer framstaellning av nya terapeutiskt anvaendbara 1-styrensulfonyl-2-oxo-5-hydroxi-pyrrolidinderivat. | |
| SU880251A3 (ru) | Способ получени производных тиохромана или их солей | |
| JPS6355512B2 (enExample) | ||
| Rasmussen et al. | Reactions of 4, 5-dihydro-2-thiazolamine with phenyl isothiocyanate and phenyl isocyanate: a reinvestigation | |
| HU192583B (en) | Process for preparing 4-quinolines | |
| KR910003636B1 (ko) | 벤조페논 옥심화합물의 제조방법 | |
| US3733364A (en) | 5-chloro-2-ethynylbenzyl methyl sulfoxide and its preparation | |
| KR20100075581A (ko) | 치환형 7-알릴-6-하이드록시-인단의 제조 방법 | |
| KR0139260B1 (ko) | 고리화된 이미다졸을 가지는 벤즈이미다졸 유도체 | |
| KR0159511B1 (ko) | 신규의 퀴놀린유도체 및 그 제조방법 | |
| KR810001980B1 (ko) | 2, 5-디히드로-1, 2-티아지노 [5, 6-b] 인돌-3-카복사미드-1, 1-디옥사이드의 제조방법 | |
| JP3567248B2 (ja) | １，２−ベンゾイソチアゾリン−３−オン化合物の製造方法 | |
| US6410760B1 (en) | Process to prepare androst-4-en-17-carboxylic acid | |
| JP2711435B2 (ja) | 新規な２，３−ジヒドロ−４ｈ−１−ベンゾピラン−４−オン誘導体またはその塩 | |
| KR0179320B1 (ko) | (±)-2-(톨릴술피닐)-시클로펜타데칸-1-온 및 그의 제법 | |
| JPH11302216A (ja) | ジアルコキシ置換インダノン誘導体の製造方法 | |
| JPH0324047A (ja) | フェニルマロン酸モノアニリド誘導体および３―フェニル―２―キノロン誘導体の製造方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HMM4 | Cancellation of final prot. due to non-payment of fee |